Camberlogo (Camberlogo)
Pregabalin Capsule
Product Images NDC 82804-184
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Pregabalinfigure1 (Pregabalinfigure1)
A line graph showing the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares pregabalin dosages of 25 mg, 100 mg, and 200 mg taken three times a day, along with a placebo group, illustrating differences in pain improvement among the groups.*
Pregabalinfigure10 (Pregabalinfigure10)
A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR over days, comparing Pregabalin and placebo groups. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis represents the number of days, up to 180 days.*
Pregabalinfigure11 (Pregabalinfigure11)
A line graph comparing the percent of subjects improved from baseline to Week 12 using the BOCF method for Pregabalin versus placebo. The x-axis shows percent improvement, and the y-axis shows the percent of subjects improved. Two lines represent Pregabalin (higher) and placebo (lower) across the improvement range.*
Pregabalinfigure12 (Pregabalinfigure12)
A graph displaying the percentage of subjects improved over time from baseline to Week 16, comparing Pregabalin to a placebo. The x-axis represents time in hours, and the y-axis shows the percentage of subjects improved, with Pregabalin and placebo represented by distinct lines.*
Pregabalinfigure2 (Pregabalinfigure2)
A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two lines represent Pregabalin 100 mg three times a day versus placebo, showing higher patient improvement percentages for Pregabalin across pain improvement levels.*
Pregabalinfigure3 (Pregabalinfigure3)
A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares the effects of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day to placebo, illustrating trends in patient improvement by dosage over a range of pain improvement percentages.*
Pregabalinfigure4 (Pregabalinfigure4)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline among three groups: Pregabalin 200 mg three times daily, Pregabalin 100 mg three times daily, and placebo. The graph depicts higher improvement percentages for the 200 mg group compared to the 100 mg group and placebo.*
Pregabalinfigure5 (Pregabalinfigure5)
A line graph showing the percentage of patients improved compared to percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved.*
Pregabalinfigure6 (Pregabalinfigure6)
A bar chart comparing responder rates (%) in two studies (E1 and E3) with various dosages of pregabalin and placebo. The x-axis shows different treatment groups including placebo and pregabalin doses at 150 mg/day, 300 mg/day, 600 mg/day, and 600 mg/day plus additional dosing. The y-axis represents the responder rate percentage up to 60%. The chart highlights statistically significant differences between pregabalin and placebo groups.*
Pregabalinfigure7 (Pregabalinfigure7)
A dose-response chart showing seizure reduction by median percentage change from baseline against dose in mg/day for Pregabalin. It compares seizure reduction across four study groups labeled E1 BID, E2 TID, E3 BID, and E3 TID, with statistical significance p-values indicated for different doses.*
Pregabalinfigure8 (Pregabalinfigure8)
A bar chart showing responder rates (%) for Pregabalin at different doses compared to placebo. The x-axis shows groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day with sample sizes 93, 103, and 96 respectively. The y-axis indicates responder rates, with values of 22.6% for placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day.*
Pregabalinfigure9 (Pregabalinfigure9)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg compared to placebo. The graph depicts higher patient improvement percentages with Pregabalin doses than placebo across pain improvement percentages ranging from 0 to 100.*
Pregabalinstructure (Pregabalinstructure)
Chemical structure of pregabalin, showing its molecular arrangement including amino, carboxyl, and methyl groups as part of the compound's formula.*
82804-184-30 (Pregablin Capsules 50 Container 60)
Label of Pregabalin 50 mg capsules by Proficient Rx LP, prescription-only Schedule C-V, containing 30 capsules. Label notes the capsule description as white hard gelatin with imprint '139' on cap and 'J' on body. Manufacturer is Hetero Labs Limited, Hyderabad, India. Storage at 20°-25°C advised.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
